TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

UPDATE ON THE IMPLEMENTATION OF THE SHAREHOLDING INCREASE PLAN BY THE CONTROLLING SHAREHOLDER

The board of directors (the "Board") and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the "Company") hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

1. INTRODUCTION

The Board refers to the announcement dated 5 February 2026 made by the Company in relation to the increase in the shareholding of S-Shares of the Company by the controlling shareholder and the proposed subsequent shareholding increase plan (the "**Previous Announcement**").

Unless otherwise defined, all capitalised terms used and not defined herein shall have the same meanings ascribed to them in the Previous Announcement.

As disclosed in the Previous Announcement, JinYao Global Pte. Ltd. (津药国际有限公司) ("**JinYao Global**")[1], a wholly-owned subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) ("**TPH**"), proposed to further increase its shareholding in the S-Shares of the Company during the six-month period commencing on 4 February 2026 through the trading system of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and by such means as may be permitted under the rules of the SGX-ST (the "**Shareholding Increase Plan**"). Under the Shareholding Increase Plan, the purchase price shall not exceed US$4 per S-Share, and the aggregate consideration (including the consideration paid for the acquisition of the 82,200 S-Shares on 4 February 2026) shall not be less than RMB14.3 million and shall not exceed RMB28.59 million.

2. UPDATE ON THE IMPLEMENTATION OF THE SHAREHOLDING INCREASE PLAN

The implementation period of the Shareholding Increase Plan expired on 3 August 2026, and the Board wishes to provide an update on the implementation of the Shareholding Increase Plan as follows:

2.1 Implementation of the Shareholding Increase Plan

During the period from 4 February 2026 to 3 August 2026, JinYao Global acquired an aggregate of 724,200 S-Shares (including the 82,200 S-Shares acquired on 4 February 2026, as disclosed in the Previous Announcement) through on-market transactions via the trading system of the SGX-ST, for an aggregate consideration of US$2,096,201.93 (equivalent to approximately

---

[1] Formerly known as Tianjin Pharmaceutical (Singapore) International Investment Pte. Ltd. (天津医药集团 (新加坡) 国际投资有限公司).

RMB14,305,902.11), at an average purchase price of US$2.8945 per S-Share. The S-Shares acquired represent approximately 0.094% of the total issued share capital of the Company as at the date of this announcement.

TPH's shareholding before and after the implementation of the Shareholding Increase Plan is set out below:

Shareholding	**Before the Implementation of the Shareholding Increase Plan**	**After the Implementation of the Shareholding Increase Plan**
Total Number of Shares	331,120,528	331,844,728
- A-Shares	325,855,528	325,855,528
- S-Shares	5,265,000	5,989,200
Total Shareholding Percentage	42.997%	43.091%

2.2 Other Relevant Information

The shareholding increase by TPH was undertaken in accordance with the Shareholding Increase Plan as set out in the Previous Announcement. The aggregate consideration paid for the shareholding increase was within the contemplated range, and the actual purchase price per S-Share did not exceed the maximum purchase price specified under the Shareholding Increase Plan. There were no other instances of non-compliance with the undertaking(s) given in connection with the Shareholding Increase Plan.

The shareholding increase by TPH was carried out in compliance with the applicable laws, regulations, departmental rules and regulatory requirements, including the Securities Law of the People's Republic of China and the Securities and Futures Act 2001 of Singapore.

The implementation of the Shareholding Increase Plan will not result in the Company's public float falling below the applicable listing requirements, nor will it lead to any change in the controlling shareholder of the Company or otherwise result in any change in the Company's control structure.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
4 August 2026